Insider trade

Grace Therapeutics (GRCE): 10% owner bought ~$50K

Opaleye Management Inc., 10% owner at Grace Therapeutics, bought ~$50K of Grace Therapeutics shares.

~$50K
Approx. value · 29K sh @ $1.72
3.1M
Holds after · shares reported
Traded
Nov 17, 2026
Filed
Nov 19, 2026

What stands out in this filing

  • The purchase added 1.0% to the shares this insider held before it; the filing reports 3,099,930 shares, held indirectly afterwards.
  • 29,207 shares at an average of $1.72 each, as reported on the form.
  • The first open-market purchase by this insider in 0 months.
  • GRCE closed at $1.72 on Nov 17, 2026, at its 52-week low, after a 17% drop over the previous 30 trading days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, 5 days earlier (Nov 12, 2026).

  1. Insider10% owner purchased ~$21K of GRCE shares in the open market
  2. Insider10% owner purchased ~$11K of GRCE shares in the open market
  3. Insider10% owner purchased ~$16K of GRCE shares in the open market
  4. Insider10% owner purchased ~$79K of GRCE shares in the open market
  5. Insider10% owner purchased ~$41K of GRCE shares in the open market
  6. Insider10% owner purchased ~$3.5K of GRCE shares in the open market
  7. Insider10% owner purchased ~$4.2K of GRCE shares in the open market
  8. Insider10% owner purchased ~$11K of GRCE shares in the open market
  9. Insider10% owner purchased ~$15K of GRCE shares in the open market
  10. Insider10% owner purchased ~$22K of GRCE shares in the open market
  11. Insider10% owner purchased ~$46K of GRCE shares in the open market
  12. Insider10% owner purchased ~$69K of GRCE shares in the open market
  13. Insider10% owner purchased ~$8K of GRCE shares in the open market
  14. Insider10% owner purchased ~$41K of GRCE shares in the open market
  15. Insider10% owner purchased ~$117K of GRCE shares in the open market
  16. Insider · 9 days before results10% owner purchased ~$18K of GRCE shares in the open market
  17. Insider · 8 days before results10% owner purchased ~$9.1K of GRCE shares in the open market
  18. Insider · 7 days before results10% owner purchased ~$5.5K of GRCE shares in the open market
  19. Company filing · Form 8-K · ResultsReported its results
  20. 5% stakeNantahala Capital Management, LLC reported a passive stake (13G) of 7.5%
  21. 5% stakeADAR1 Capital Management, LLC reported a passive stake (13G) of 9.9%
  22. Insider10% owner purchased ~$28K of GRCE shares in the open market
  23. Insider10% owner purchased ~$50K of GRCE shares in the open market

What came next

  1. Insider10% owner purchased ~$5.1K of GRCE shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Grace Therapeutics

For Grace Therapeutics, OQRO holds 24 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GRCE page.

Other recent filings by Opaleye Management Inc., 10% owner

The full history of Opaleye Management Inc., 10% owner is on the profile page.

How this filing works

Explore the data

Common questions

Which Grace Therapeutics (GRCE) insider traded, and how much?

Opaleye Management Inc., 10% owner at Grace Therapeutics, bought ~$50K of Grace Therapeutics shares. 29K shares at $1.72, open market.

When did it happen, and when was it made public?

Traded: Nov 17, 2026. Filed: Nov 19, 2026. That is 2 days between the two dates.

What stands out in this filing?

The purchase added 1.0% to the shares this insider held before it; the filing reports 3,099,930 shares, held indirectly afterwards. 29,207 shares at an average of $1.72 each, as reported on the form. The first open-market purchase by this insider in 0 months.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Grace Therapeutics recently?

For Grace Therapeutics, OQRO holds 24 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the GRCE page.

Does this mean GRCE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Grace Therapeutics

Everything OQRO holds on this company is on its GRCE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data